With our cutting-edge in silico drug discovery capabilities 👉 https://www.pharmidex.com/In-silico

Pharmidex   is committed to accelerating the development of novel therapies targeting GLP-1 receptors, a promising path in the fight against obesity and type 2 diabetes.

By combining our in silico expertise, including molecular docking, virtual screening and structure-based design, with our well-established in vivo obesity models, we offer a powerful, integrated platform to uncover and validate new therapeutic candidates more efficiently.

Whether you're a pharma company, CRO, biotech, or academic institution, Pharmidex is ready to collaborate and support your discovery efforts from computational predictions to real-world preclinical validation.

🤝 Let’s combine strengths and accelerate innovation in metabolic disease research to improve human health globally.